{"id":18577,"date":"2021-07-30T08:01:29","date_gmt":"2021-07-30T12:01:29","guid":{"rendered":"https:\/\/medicarereport.org\/?p=18577"},"modified":"2021-07-30T08:01:29","modified_gmt":"2021-07-30T12:01:29","slug":"a-new-alzheimers-drug-comes-with-lots-of-questions-about-how-to-use-it","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=18577","title":{"rendered":"A New Alzheimer&#8217;s Drug Comes With Lots Of Questions About How To Use It"},"content":{"rendered":"<p>(By\u00a0Jon Hamilton for NPR)<\/p>\n<p>Nearly two months after the Alzheimer&#8217;s drug Aduhelm received conditional approval from the Food and Drug Administration, experts are still debating how, and whether, it should be used.<\/p>\n<p>A few doctors and medical institutions say they have no plans to administer Aduhelm. Many more are trying to decide which patients should have access to the drug and how to protect them from its potentially dangerous side effects.\u00a0 Continue reading the article <a href=\"https:\/\/www.npr.org\/sections\/health-shots\/2021\/07\/29\/1022263054\/a-new-alzheimers-drug-comes-with-lots-of-questions-about-how-to-use-it\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-3902\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\" alt=\"\" width=\"152\" height=\"55\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png 152w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo-150x55.png 150w\" sizes=\"auto, (max-width: 152px) 100vw, 152px\" \/><\/a><\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By\u00a0Jon Hamilton for NPR) Nearly two months after the Alzheimer&#8217;s drug Aduhelm received conditional approval from the Food and Drug<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,15],"tags":[],"class_list":["post-18577","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18577"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18577\/revisions"}],"predecessor-version":[{"id":18578,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18577\/revisions\/18578"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}